Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

Core Viewpoint - Bionano Genomics' optical genome mapping (OGM) technology has demonstrated the ability to identify a specific variant in acute promyelocytic leukemia (APL) that is often missed by traditional cytogenetic methods, suggesting OGM could enhance therapy selection and patient management in blood cancers [1][2][3]. Group 1: OGM Technology and Findings - OGM successfully detected a PML::RARA fusion variant in APL that was not identified by karyotyping and was non-informative by FISH [2][7]. - APL, a subtype of acute myelogenous leukemia (AML), has a treatment response rate to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), but conventional cytogenetics fails to identify actionable variants in approximately 13% of APL cases [2][7]. - The identification of the PML::RARA fusion variant by OGM aligns with previous findings that OGM can detect both variants identified by standard cytogenetics and additional pathogenic variants that are often missed [2][7]. Group 2: Company Overview - Bionano Genomics specializes in genome analysis solutions aimed at transforming genomic insights through OGM, diagnostic services, and software [4]. - The company provides OGM solutions applicable across various research domains, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions utilizing proprietary isotachophoresis technology [4]. - Bionano also offers OGM-based diagnostic testing services through its subsidiary, Lineagen, Inc. [4].